Dai ichi Life Insurance Company Ltd Sells 10,200 Shares of Insulet Co. (NASDAQ:PODD)

Dai ichi Life Insurance Company Ltd decreased its position in shares of Insulet Co. (NASDAQ:PODD - Free Report) by 71.9% during the third quarter, according to its most recent filing with the SEC. The firm owned 3,988 shares of the medical instruments supplier's stock after selling 10,200 shares during the period. Dai ichi Life Insurance Company Ltd's holdings in Insulet were worth $928,000 at the end of the most recent quarter.

Several other institutional investors have also recently made changes to their positions in the company. Baillie Gifford & Co. lifted its position in Insulet by 20.7% during the 3rd quarter. Baillie Gifford & Co. now owns 2,275,701 shares of the medical instruments supplier's stock valued at $529,669,000 after acquiring an additional 389,639 shares during the period. Clearbridge Investments LLC lifted its holdings in shares of Insulet by 6.0% during the second quarter. Clearbridge Investments LLC now owns 1,339,763 shares of the medical instruments supplier's stock valued at $270,364,000 after purchasing an additional 75,526 shares during the last quarter. American Century Companies Inc. lifted its holdings in shares of Insulet by 18.7% during the second quarter. American Century Companies Inc. now owns 885,669 shares of the medical instruments supplier's stock valued at $178,728,000 after purchasing an additional 139,246 shares during the last quarter. Westfield Capital Management Co. LP boosted its position in shares of Insulet by 27.6% in the 3rd quarter. Westfield Capital Management Co. LP now owns 754,872 shares of the medical instruments supplier's stock worth $175,697,000 after purchasing an additional 163,388 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. grew its stake in shares of Insulet by 43.8% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 636,265 shares of the medical instruments supplier's stock worth $148,091,000 after buying an additional 193,839 shares during the last quarter.

Insulet Stock Performance

Shares of NASDAQ:PODD traded down $0.14 during trading on Friday, hitting $266.78. The company's stock had a trading volume of 209,678 shares, compared to its average volume of 769,880. The company has a debt-to-equity ratio of 1.21, a current ratio of 3.68 and a quick ratio of 2.80. The firm has a market cap of $18.71 billion, a price-to-earnings ratio of 45.57, a P/E/G ratio of 4.08 and a beta of 1.22. The company has a 50-day moving average of $243.79 and a 200-day moving average of $213.11. Insulet Co. has a 12 month low of $160.19 and a 12 month high of $279.40.

Analyst Upgrades and Downgrades

Several equities research analysts have commented on PODD shares. Piper Sandler boosted their target price on Insulet from $230.00 to $285.00 and gave the stock an "overweight" rating in a report on Tuesday, September 17th. Citigroup increased their price objective on shares of Insulet from $250.00 to $275.00 and gave the company a "buy" rating in a research report on Tuesday, October 1st. Morgan Stanley lifted their target price on shares of Insulet from $234.00 to $317.00 and gave the stock an "overweight" rating in a report on Monday, November 11th. UBS Group increased their price target on shares of Insulet from $211.00 to $223.00 and gave the company a "neutral" rating in a report on Friday, August 9th. Finally, Canaccord Genuity Group boosted their price objective on shares of Insulet from $236.00 to $269.00 and gave the stock a "buy" rating in a report on Wednesday, September 25th. Three research analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company's stock. Based on data from MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus price target of $253.27.

Insulet Company Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.